Efficacy of Polymyxin B Hemoperfusion for Treatment of Sepsis.

IF 1.5 Q3 CRITICAL CARE MEDICINE Indian Journal of Critical Care Medicine Pub Date : 2024-10-01 Epub Date: 2024-09-30 DOI:10.5005/jp-journals-10071-24805
Indranil Ghosh, Sukhwinder Sangha, Gaurav Pandey, Atul Srivastava
{"title":"Efficacy of Polymyxin B Hemoperfusion for Treatment of Sepsis.","authors":"Indranil Ghosh, Sukhwinder Sangha, Gaurav Pandey, Atul Srivastava","doi":"10.5005/jp-journals-10071-24805","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To study the efficacy of polymyxin B hemoperfusion in addition to standard care for sepsis treatment.</p><p><strong>Materials and methods: </strong>Fifty sepsis patients (mean age 54.26 ± 14.64 years; 68% males) were randomized to either the case group (<i>n</i> = 25; receiving Polymyxin B hemoperfusion in addition to standard ICU care) or the control group (<i>n</i> = 25; receiving standard ICU care only). The patients were followed up at frequent intervals of 6, 12, 24, 48, and 72 hours. A last follow-up on day 7 was done. The duration of the ICU stay and survival until day 7 were recorded. Changes in clinical and biochemical parameters were also noted and compared.</p><p><strong>Results: </strong>Mean sequential organ failure assessment (SOFA) scores at admission were 3.44 ± 1.00 and 2.80 ± 0.82, respectively, in cases and controls. Cases as compared to controls showed faster, and sustainable improvement. No significant difference between the two groups was seen for mortality at day 7.</p><p><strong>Conclusion: </strong>Polymyxin B hemoperfusion tends to show a faster recovery and a non-significant trend towards reduced mortality in ICU-admitted sepsis patients.</p><p><strong>How to cite this article: </strong>Ghosh I, Sangha S, Pandey G, Srivastava A. Efficacy of Polymyxin B Hemoperfusion for Treatment of Sepsis. Indian J Crit Care Med 2024;28(10):930-934.</p>","PeriodicalId":47664,"journal":{"name":"Indian Journal of Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11471987/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Critical Care Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5005/jp-journals-10071-24805","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: To study the efficacy of polymyxin B hemoperfusion in addition to standard care for sepsis treatment.

Materials and methods: Fifty sepsis patients (mean age 54.26 ± 14.64 years; 68% males) were randomized to either the case group (n = 25; receiving Polymyxin B hemoperfusion in addition to standard ICU care) or the control group (n = 25; receiving standard ICU care only). The patients were followed up at frequent intervals of 6, 12, 24, 48, and 72 hours. A last follow-up on day 7 was done. The duration of the ICU stay and survival until day 7 were recorded. Changes in clinical and biochemical parameters were also noted and compared.

Results: Mean sequential organ failure assessment (SOFA) scores at admission were 3.44 ± 1.00 and 2.80 ± 0.82, respectively, in cases and controls. Cases as compared to controls showed faster, and sustainable improvement. No significant difference between the two groups was seen for mortality at day 7.

Conclusion: Polymyxin B hemoperfusion tends to show a faster recovery and a non-significant trend towards reduced mortality in ICU-admitted sepsis patients.

How to cite this article: Ghosh I, Sangha S, Pandey G, Srivastava A. Efficacy of Polymyxin B Hemoperfusion for Treatment of Sepsis. Indian J Crit Care Med 2024;28(10):930-934.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
多粘菌素 B 血液灌流治疗败血症的疗效。
目的:研究多粘菌素 B 血液灌流治疗败血症的疗效:研究多粘菌素B血液灌流在脓毒症治疗标准护理之外的疗效:将 50 名脓毒症患者(平均年龄为 54.26 ± 14.64 岁;68% 为男性)随机分为病例组(n = 25;在接受标准重症监护室护理的同时接受多粘菌素 B 血液灌流)或对照组(n = 25;仅接受标准重症监护室护理)。每隔 6、12、24、48 和 72 小时对患者进行一次随访。最后一次随访在第 7 天进行。记录了重症监护室的住院时间和第 7 天前的存活率。同时还记录并比较了临床和生化指标的变化:结果:病例和对照组入院时的器官功能衰竭顺序评估(SOFA)平均得分分别为 3.44 ± 1.00 和 2.80 ± 0.82。与对照组相比,病例的病情改善更快、更持久。两组患者在第 7 天的死亡率无明显差异:结论:多粘菌素 B 血液灌流可使重症监护室收治的脓毒症患者更快康复,并有降低死亡率的非显著趋势:Ghosh I, Sangha S, Pandey G, Srivastava A. 多粘菌素B血液灌流治疗败血症的疗效。Indian J Crit Care Med 2024;28(10):930-934.
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.50
自引率
10.00%
发文量
299
期刊介绍: Indian Journal of Critical Care Medicine (ISSN 0972-5229) is specialty periodical published under the auspices of Indian Society of Critical Care Medicine. Journal encourages research, education and dissemination of knowledge in the fields of critical and emergency medicine.
期刊最新文献
Care Beyond Cure: Humanizing the Intensive Care Unit Journey. Clinical Characteristics of Obstetric Patients Admitted in ICU During COVID-19 Pandemic and its Comparison with Pre-COVID Period: A Retrospective Analysis from North India. Communication, Shared Decision-making and Goals of Care in the ICU through Electronic Health Records: A Scoping Review. Comparison of Nebulized Glycopyrronium with a Combination of Salbutamol and Ipratropium on Ventilatory Parameters in Critically Ill Mechanically Ventilated Patients of Chronic Obstructive Pulmonary Disease: An Observational Study. Comparison of Trends of Procalcitonin and Neutrophil to Lymphocyte Ratio in Patients of Sepsis in Intensive Care Unit.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1